title: Horizons in therapy for corneal angiogenesis.
abstract: Corneal neovascularization can lead to a devastating disease process that involves the breakdown of the limbal barrier and the formation of blood vessels in the cornea, leading to severe visual impairment. This review discusses the delicate balance between antiangiogenic and angiogenic factors that govern the antiangiogenic privilege of the cornea. Current treatment methods, clinical trials, and future prospects in the management of corneal neovascularization also are discussed.
authors.affiliation: Department of Ophthalmology and Visual Sciences, John A. Moran Eye Center, University of Utah, Salt Lake City, Utah 84132, USA.
authors.forename: Surekha
authors.initials: S
authors.lastname: Maddula
authors.forename: Don K
authors.initials: DK
authors.lastname: Davis
authors.forename: Soumya
authors.initials: S
authors.lastname: Maddula
authors.forename: Michael K
authors.initials: MK
authors.lastname: Burrow
authors.forename: Balamurali K
authors.initials: BK
authors.lastname: Ambati
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D002199:Capillary Permeability; D003315:Cornea / Q000098:blood supply; D016510:Corneal Neovascularization / Q000628:therapy*; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D010778:Photochemotherapy
chemical_list: D020533:Angiogenesis Inhibitors; D005938:Glucocorticoids